Kimia Biosciences (BOM:530313) Debt-to-Equity : 0.00 (As of . 20)

View and export this data going back to 2017. Start your Free Trial

What is Kimia Biosciences Debt-to-Equity?

Kimia Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₹0.00 Mil. Kimia Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₹0.00 Mil. Kimia Biosciences's Total Stockholders Equity for the quarter that ended in . 20 was ₹0.00 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kimia Biosciences's Debt-to-Equity or its related term are showing as below:

BOM:530313's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.27
* Ranked among companies with meaningful Debt-to-Equity only.

Kimia Biosciences Debt-to-Equity Historical Data

The historical data trend for Kimia Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kimia Biosciences Debt-to-Equity Chart

Kimia Biosciences Annual Data

Trend

Debt-to-Equity

Kimia Biosciences Semi-Annual Data

Debt-to-Equity

Competitive Comparison of Kimia Biosciences's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Kimia Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kimia Biosciences's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kimia Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kimia Biosciences's Debt-to-Equity falls into.

Kimia Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kimia Biosciences's Debt to Equity Ratio for the fiscal year that ended in . 20 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(	+	)	/	N/A
	=	N/A

Kimia Biosciences's Debt to Equity Ratio for the quarter that ended in . 20 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(	+	)	/
	=	N/A

Kimia Biosciences (BOM:530313) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Kimia Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kimia Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kimia Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kimia Biosciences Ltd (BOM:530313) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

Netaji Subhash Place, 974, 9th Floor, Aggarwal Millenium Tower-II, Pitampura, New Delhi, IND, 110 034

Website

https://www.kimiabiosciences.com

Kimia Biosciences Ltd is a company engaged in the manufacturing of bulk drugs. Some of the company's products include Azelnidipine, Deflazacort, Oxaceprol, Seratodast, and Tretinoin among others. Its only operating segment being Pharmaceuticals.

Kimia Biosciences Headlines

No Headlines